3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
8
Unknown
3
Terminated
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
15
Thoracic
10
Genitourinary
5
Head & Neck
3
Gynecologic
2
Tumor-Agnostic
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Conditions
Mesothelioma, Malignant
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Interventions
pembrolizumab
27
Pemetrexed
10
Nivolumab
10
Cyclophosphamide
10
Carboplatin
10
atezolizumab
8
Specimen Handling
8
Cisplatin
8
Ipilimumab
6
Biopsy
6
fludarabine
5
Injections
5
tislelizumab
4
spartalizumab
4
Vincristine
4
Radiotherapy
4
Proton Therapy
4
Platinum
4
Paclitaxel
4
Drug Therapy
4
Docetaxel
4
Bevacizumab
4
1,2-diaminocyclohexaneplatinum II citrate
4
sintilimab
3
durvalumab
3
Trastuzumab
3
Etoposide
3
Cetuximab
3
zimberelimab
2
trametinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
tremelimumab
×
Other solid neoplasm
×
Clear all
NCT01843374
2026-03-05
Tremelimumab
MedImmune LLC
Phase 2
Active not recruiting
571 enrolled
19 charts